Magnesium and Asthma - Clinical Trials

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Asthma currently affects an estimated 15 million Americans. A number of studies have found an association between low dietary magnesium (Mg) intake and increased asthma incidence and severity of symptoms. However, clinical intervention trials are necessary to directly assess whether there is a true protective or preventative causal relationship between low Mg and asthma. In our study, we will assess the effects of 6 1/2 months of oral Mg supplements or placebo on clinical markers of asthma control, indirect biomarkers of inflammation, bronchial hyperresponsiveness, and indices of oxidative defense and damage in subjects with mild to moderate persistent asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Criteria

• Mild to moderate persistent asthma (NAEPP 1997 revised guidelines)

• Current use of inhaled beta-2- agonists or steroid inhaler therapy only (No use of prednisone in past 3 months)

• No use of products (i.e. antacids, laxatives, supplements) containing more than 50 mg Mg daily in the last 3 months

• No current use of theophylline, leukotriene antagonists, or other systemic immunomodulating compounds

• Nonsmoker

• No concurrent pulmonary disease (pulmonary hypertension, cystic fibrosis, sarcoidosis, bronchiectasis, hypersensitivity pneumonitis, restrictive lung disease, abnormal DLCOva)

• No concurrent medical diagnoses (alcoholism, coronary artery disease, diabetes, HIV infection, chronic hepatitis, uncontrolled hypertension, chronic renal failure or a psychiatric disorder that is judged to make full participation difficult)

• Not pregnant or lactating.